In a first, Glenmark Pharma launches pulmonary fibrosis treatment drug in India at affordable cost, clinical trials being rolled out to study the efficacy and safety of Nintedanib as a treatment of SARS-COV2 induced pulmonary fibrosis in moderate to severe COVID-19 patients
from Hindustan Times - lifestyle https://ift.tt/3k0wQhW
0 Comments